Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SJR Rank #1,792H-index: 79SJR: 1.774Best quartile: Q1Open AccessAPC: US$2,540Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Inc

Country

United States

Type

journal

SJR by Edition

2022202500.511.52

Subject Categories

  • Neurology (clinical)Q1
  • Psychiatry and Mental HealthQ1

Areas: Medicine

Most published research topics

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsFunctional Brain Connectivity StudiesTraumatic Brain Injury ResearchIntracerebral and Subarachnoid Hemorrhage ResearchCancer-related cognitive impairment studiesIntensive Care Unit Cognitive DisordersNeurobiology of Language and BilingualismNeurological Disease Mechanisms and TreatmentsDown syndrome and intellectual disability research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0100200300400

Documents per Year

2022202504590135180

Detailed Information

ISSN

2352-8729

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

4.63

References per Document

41.18

Coverage

2015-2026

Scope

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer's Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.

Metrics from SCImago Journal Rank 2025. View on SCImago